Last 47 quarters of trend data · Healthcare · Medical - Devices
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 27.83 | 41.40 | 30.71 | 35.62 | 33.67 | 43.73 | 5.37 | 30.32 | 35.10 | 40.59 | 30.24 | 29.53 | 34.94 | 33.75 | 46.52 | 29.86 | 23.83 | 21.44 | 31.42 | 25.24 | 43.91 |
| — | -5.3% | +472.3% | +17.5% | -4.1% | +7.7% | -82.3% | +2.7% | +0.5% | +20.3% | -35.0% | -1.1% | +46.7% | +57.4% | +48.1% | +18.3% | -45.7% | -28.4% | +38.9% | -36.0% | -42.4% | |
| P/S Ratio | 4.07 | 4.02 | 4.78 | 5.15 | 5.34 | 5.59 | 4.50 | 4.68 | 4.38 | 4.99 | 4.70 | 4.17 | 4.78 | 4.55 | 4.77 | 4.10 | 4.26 | 4.42 | 5.47 | 4.83 | 5.08 |
| — | -28.2% | +6.1% | +10.0% | +21.9% | +12.1% | -4.2% | +12.3% | -8.3% | +9.7% | -1.6% | +1.8% | +12.3% | +3.0% | -12.7% | -15.2% | -16.2% | -14.0% | +19.5% | -12.0% | -8.7% | |
| P/B Ratio | 3.43 | 3.40 | 4.15 | 4.57 | 4.69 | 4.72 | 4.12 | 4.98 | 4.60 | 5.09 | 4.96 | 4.49 | 5.10 | 4.76 | 5.22 | 4.76 | 5.22 | 5.90 | 6.96 | 6.10 | 6.11 |
| — | -28.0% | +0.6% | -8.2% | +1.9% | -7.3% | -16.8% | +10.8% | -9.8% | +6.9% | -5.0% | -5.6% | -2.3% | -19.2% | -25.0% | -22.0% | -14.5% | -7.2% | +17.3% | -0.9% | +15.3% | |
| P/FCF | 24.38 | 48.95 | 20.84 | 25.56 | 38.54 | 62.10 | 22.99 | 23.18 | 31.88 | 79.31 | 21.07 | 32.14 | 68.54 | 58.12 | 28.06 | 18.45 | 23.61 | 30.12 | 25.56 | 23.59 | 30.30 |
| — | -21.2% | -9.3% | +10.3% | +20.9% | -21.7% | +9.1% | -27.9% | -53.5% | +36.5% | -24.9% | +74.2% | +190.4% | +93.0% | +9.8% | -21.8% | -22.1% | +25.7% | +62.8% | -23.9% | -49.5% | |
| EV / EBITDA | 17.31 | 20.08 | 21.08 | 21.04 | 21.62 | 24.39 | 18.34 | 19.73 | 19.04 | 23.65 | 18.81 | 17.80 | 21.62 | 20.98 | 22.31 | 17.62 | 15.82 | 14.80 | 19.54 | 15.89 | 18.95 |
| — | -17.7% | +15.0% | +6.6% | +13.5% | +3.1% | -2.5% | +10.9% | -11.9% | +12.8% | -15.7% | +1.0% | +36.7% | +41.8% | +14.2% | +10.9% | -16.5% | -19.4% | +22.7% | -31.1% | -37.6% | |
| EV / EBIT | 23.22 | 34.05 | 23.48 | 26.04 | 26.93 | 31.18 | 23.50 | 24.54 | 26.72 | 33.36 | 24.80 | 24.48 | 27.92 | 26.84 | 33.80 | 24.46 | 20.47 | 19.01 | 26.93 | 21.10 | 36.68 |
| — | +9.2% | -0.1% | +6.1% | +0.8% | -6.5% | -5.2% | +0.2% | -4.3% | +24.3% | -26.6% | +0.1% | +36.4% | +41.2% | +25.5% | +16.0% | -44.2% | -28.8% | +29.0% | -37.4% | -43.4% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 55.5% | 56.3% | 57.0% | 55.7% | 56.4% | 52.6% | 51.0% | 51.0% | 51.1% | 50.4% | 51.3% | 49.6% | 49.6% | 49.3% | 49.3% | 50.0% | 51.3% | 53.5% | 54.1% | 55.5% | 52.6% |
| — | +7.1% | +11.8% | +9.3% | +10.4% | +4.3% | -0.6% | +2.8% | +3.2% | +2.2% | +4.2% | -0.8% | -3.4% | -7.9% | -9.0% | -9.8% | -2.4% | +0.5% | +1.9% | +13.3% | +10.7% | |
| Operating Margin | 18.2% | 16.5% | 19.6% | 18.1% | 18.4% | 16.3% | 18.1% | 17.1% | 16.2% | 13.9% | 18.2% | 16.5% | 15.1% | 14.4% | 14.3% | 16.4% | 20.7% | 24.3% | 21.3% | 24.0% | 19.5% |
| — | +1.2% | +8.3% | +5.8% | +13.4% | +17.2% | -0.4% | +3.3% | +7.3% | -3.2% | +27.5% | +1.1% | -26.9% | -40.8% | -33.1% | -31.8% | +6.0% | +18.9% | -5.4% | +45.9% | +123.1% | |
| Net Margin | 14.7% | 9.6% | 15.5% | 14.5% | 16.0% | 12.8% | 84.1% | 15.5% | 12.5% | 12.3% | 15.6% | 14.2% | 13.8% | 13.5% | 10.2% | 13.8% | 17.9% | 20.6% | 17.3% | 19.2% | 11.6% |
| — | -24.6% | -81.6% | -6.6% | +27.3% | +4.0% | +440.3% | +9.3% | -8.9% | -9.1% | +52.0% | +2.7% | -23.1% | -34.3% | -41.0% | -28.3% | +54.1% | +20.0% | -14.2% | +38.1% | +58.7% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 13.0% | 2.0% | 3.4% | 3.2% | 3.6% | 2.7% | 21.0% | 4.1% | 3.3% | 3.1% | 4.2% | 3.8% | 3.7% | 3.6% | 2.8% | 4.0% | 5.6% | 6.8% | 5.6% | 6.1% | 3.5% |
| — | -25.3% | -83.7% | -22.1% | +7.5% | -13.1% | +403.9% | +8.2% | -10.1% | -11.5% | +46.8% | -3.3% | -34.0% | -47.9% | -49.6% | -35.4% | +59.1% | +27.2% | -15.9% | +54.9% | +99.9% | |
| ROA | 7.8% | 1.1% | 2.1% | 2.0% | 2.2% | 1.6% | 11.8% | 2.2% | 1.8% | 1.7% | 2.2% | 2.0% | 1.9% | 1.8% | 1.4% | 2.0% | 2.7% | 3.3% | 2.7% | 2.9% | 1.6% |
| — | -32.8% | -82.5% | -12.5% | +20.1% | -3.3% | +440.1% | +13.1% | -4.2% | -5.4% | +56.4% | +1.1% | -31.4% | -45.8% | -47.4% | -31.6% | +67.3% | +32.9% | -12.6% | +59.7% | +105.5% | |
| ROIC | 10.5% | 2.0% | 2.9% | 2.7% | 2.7% | 2.3% | 2.9% | 2.9% | 2.7% | 2.2% | 3.0% | 2.7% | 2.5% | 2.3% | 2.5% | 2.9% | 3.9% | 4.8% | 4.1% | 4.5% | 3.4% |
| — | -12.8% | +0.4% | -5.9% | +1.9% | +4.2% | -2.2% | +6.2% | +7.7% | -6.5% | +20.2% | -7.5% | -36.5% | -51.2% | -40.1% | -34.8% | +14.8% | +34.8% | +4.2% | +87.9% | +221.8% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.29 | 0.65 | 0.29 | 0.25 | 0.26 | 0.27 | 0.32 | 0.37 | 0.37 | 0.37 | 0.41 | 0.41 | 0.45 | 0.45 | 0.49 | 0.46 | 0.46 | 0.48 | 0.53 | 0.53 | 0.54 |
| — | +139.4% | -10.5% | -32.5% | -29.1% | -27.8% | -22.0% | -9.2% | -17.2% | -17.7% | -15.9% | -9.9% | -1.3% | -5.4% | -9.0% | -13.9% | -16.0% | -12.1% | -11.3% | -9.6% | -14.9% | |
| Debt / EBITDA | 1.40 | 13.24 | 5.64 | 4.54 | 4.75 | 5.42 | 5.46 | 5.72 | 5.92 | 6.66 | 5.93 | 6.21 | 7.29 | 7.66 | 7.98 | 6.52 | 5.31 | 4.61 | 5.78 | 5.30 | 6.44 |
| — | +144.3% | +3.2% | -20.6% | -19.8% | -18.6% | -7.9% | -7.8% | -18.7% | -13.1% | -25.7% | -4.8% | +37.2% | +66.2% | +38.1% | +22.9% | -17.5% | -23.4% | -4.7% | -35.3% | -52.0% | |
| Current Ratio | 1.58 | 1.39 | 1.58 | 1.70 | 1.82 | 1.78 | 1.67 | 1.60 | 1.68 | 1.60 | 1.64 | 1.74 | 1.64 | 1.68 | 1.63 | 1.86 | 2.01 | 1.85 | 1.85 | 1.83 | 1.79 |
| — | -22.0% | -5.7% | +6.6% | +8.4% | +11.6% | +2.0% | -8.1% | +2.6% | -4.9% | +0.6% | -6.5% | -18.7% | -9.4% | -12.0% | +1.8% | +12.3% | +5.8% | +7.7% | +7.7% | +14.2% | |
| Quick Ratio | 1.18 | 1.01 | 1.18 | 1.24 | 1.30 | 1.27 | 1.23 | 1.14 | 1.18 | 1.11 | 1.16 | 1.23 | 1.16 | 1.22 | 1.23 | 1.43 | 1.54 | 1.40 | 1.46 | 1.42 | 1.36 |
| — | -20.6% | -4.1% | +9.1% | +10.0% | +14.5% | +6.0% | -7.2% | +2.2% | -9.0% | -5.4% | -14.1% | -24.6% | -13.1% | -15.5% | +0.9% | +12.9% | +6.4% | +12.4% | +18.8% | +24.2% | |
| Interest Coverage | 25.83 | 8.72 | 20.00 | 52.30 | 18.77 | 14.27 | 14.36 | 12.69 | 10.57 | 13.27 | 8.64 | 12.29 | 11.69 | 10.64 | 9.05 | 32.39 | 28.67 | 288.60 | 27.15 | 21.95 | 10.91 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Bull/bear thesis, analyst target revisions, and earnings execution.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ABT stock.
Abbott Laboratories's current P/E is 27.8x. The average P/E over the last 4 quarters is 35.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Abbott Laboratories's current operating margin is 18.2%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Abbott Laboratories's business trajectory between earnings reports.